Prospective pregnancy study to assess maternal and fetal outcomes following exposure to galcanezumab (I5Q-MC-B005)

04/12/2019
21/03/2024
EU PAS number:
EUPAS28151
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

I5Q-MC-B005 v1_Redacted

English (9.38 MB - PDF) View document
Updated protocol

Lilly I5Q-MC-B005 v5.0_Galcanezumab_PregReg_Protocol_Amendment_CLEAN_Redacted

First published: 22/02/2024
English (655.58 KB - PDF) View document
Study results
Study report
Other information